Company intelligence / Profile preview

NUAgo Therapeutics

Nottingham, Nottinghamshire, United Kingdom

Ownership: Private
Employees: ~5
Development stage: Other

Overview

NUAgo Therapeutics is a UK-based biotechnology company specializing in the development of regenerative medicines for nerve repair. Spun out from the University of Nottingham, the company focuses on small molecule therapeutics designed to stimulate the regrowth of damaged nerves by targeting the Nerve Up-regulation and Activation (NUA) pathway. Their primary focus is on treating peripheral nerve injuries, which currently have limited therapeutic options beyond surgery. NUAgo's approach aims to restore function and improve quality of life for patients suffering from traumatic nerve damage and potentially spinal cord injuries.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

NU-001

Preclinical

Partnerships

University of Nottingham

Beyond the preview

Go deeper on NUAgo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NUAgo Therapeutics.

Explore the full profile